"Vemurafenib (Zelboraf, Roche/Genentech), a BRAF inhibitor marketed for use in the treatment of melanoma, has now shown activity in patients with refractory papillary thyroid cancer.
For the approximately 25% to 50% of patients "...
In the event of an overdose, monitor patients closely for QTc prolongation. Because of the 19-day halflife, adverse reactions may not resolve quickly.
Last reviewed on RxList: 12/5/2016
Additional Caprelsa Information
- Caprelsa Drug Interactions Center: vandetanib oral
- Caprelsa Side Effects Center
- Caprelsa FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.